Journal Article Summary
The article focuses on hidradenitis suppurativa (HS), a chronic skin condition that causes painful lumps and scarring, and reviews various treatment options available for it. With over 50 different interventions reported, choosing the right therapy can be difficult for both patients and healthcare providers. The study aims to summarize the evidence from randomized controlled trials (RCTs) to help guide treatment decisions, emphasizing the importance of high-quality evidence in managing this challenging condition.
The researchers conducted a systematic review of RCTs involving adults with HS, assessing the quality of evidence using the GRADE system. They included 12 trials that evaluated 15 different interventions, with a median participant number of 27 and a median trial duration of 16 weeks. Key findings indicated that adalimumab administered weekly and infliximab were effective in improving patients' quality of life, while adalimumab given every other week and etanercept showed no significant benefits. However, many interventions were studied in small trials, leading to limitations in the strength of the recommendations.
The review highlights several limitations, including the small size of most studies and the lack of high-quality evidence for many treatments. Patients should be aware that while some therapies show promise, the evidence is often imprecise and may not apply to everyone. It is crucial for readers to discuss their treatment options with a healthcare professional, considering the potential benefits and risks of each intervention, as well as the need for more research in this area to improve treatment strategies for HS.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Ingram J.R., Woo P.N., Chua S.L., Ormerod A.D., Desai N., Kai A.C., Hood K., Burton T., et al.. Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. The British Journal of Dermatology 2016. DOI: 10.1111/bjd.14418. PMID: 26801356. PMCID: PMC5021164.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) --- Perrigo --- Over The Counter
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) — Perrigo — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
